Exo Therapeutics is a biotechnology startup that operates in the pharmaceutical industry, specifically in the development of innovative medicines. The company's primary focus is on modulating enzyme activity in the fields of oncology and inflammation. This means they are working on creating drugs that can control the activity of enzymes, which are proteins in the body that speed up chemical reactions. By doing this, they aim to treat diseases related to cancer and inflammation more effectively.

Their main product is the ExoSight™ platform, which they describe as a comprehensive tool to expand the universe of druggable enzymes. Essentially, this platform is designed to help them discover new enzymes that can be targeted with drugs. Their lead program is currently targeting TANK Binding Kinase 1 (TBK1), an enzyme involved in the immune response, for the treatment of autoimmune diseases.

Exo Therapeutics' business model revolves around the research, development, and eventual commercialization of these innovative drugs. They make money by developing these drugs and bringing them to market, either by selling them directly or through partnerships with larger pharmaceutical companies.

The company has recently made significant appointments to its executive team, including Alexandra Joseph, PhD, as Executive Vice President of Biology, and Nagesh Mahanthappa as Executive Chair. These appointments suggest the company is gearing up for significant growth and development in the near future.

Keywords: Biotechnology, Pharmaceuticals, Enzyme Modulation, Oncology, Inflammation, Drug Development, ExoSight™ Platform, TANK Binding Kinase 1 (TBK1), Autoimmune Diseases, Executive Appointments.